Michael D. Greicius
Functional MRI currently has few clinical applications. This is due, in part, to the difficulty of using task-activation fMRI in a clinical setting. Resting-state fMRI, which allows for the detection of 15-20 large-scale brain networks, has the potential to overcome some of these clinical limitations. This talk will examine efforts to develop resting-state fMRI biomarkers for several neuropsychiatric disorders including coma, depression and chronic pain. Particular emphasis will be placed on resting-state fMRI as a potential biomarker in Alzheimers disease.